This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: National Institute of Health and Medical Research, Université´ D'aix-Marseille, Other. Active years: 2017-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2017-2018
Title: Nacer-Eddine Serriari: Innovator in Antibody Research
Introduction
Nacer-Eddine Serriari is a notable inventor based in Amiens, France, recognized for his contributions to the field of antibody research. With two patents to his name, Serriari is at the forefront of developing innovative therapeutic solutions targeting critical interactions in immune response regulation.
Latest Patents
Nacer-Eddine Serriari's latest patents focus on groundbreaking advancements in antibody technology. His first patent entails "BTLA antibodies and uses thereof," which pertains to antibodies designed to block the BTLA-HVEM interaction, potentially offering new avenues for immune modulation. The second patent, "PD-1 antibodies and PD-L1 antibodies and uses thereof," addresses the development of PD-1 and PD-L1 antibodies, which are crucial in cancer immunotherapy.
Career Highlights
Throughout his career, Serriari has worked with reputable institutions, including Université d'Aix-Marseille. His research and innovations have played a pivotal role in enhancing understanding and treatment strategies for various diseases, particularly in the area of cancer therapy.
Collaborations
Serriari has collaborated with esteemed colleagues, including Daniel Olive and Jacques Nunes. Their collective efforts have contributed significantly to advancements in immunotherapy and the development of novel therapeutic antibodies.
Conclusion
Nacer-Eddine Serriari's work in antibody research exemplifies the impact of innovation in modern medicine. His patents not only reflect his expertise as an inventor but also signify important steps forward in the fight against various health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile